Clinical Trial Update: TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating TAS-102 (trifluridine/tipiracil) in ER-positive, HER2-negative advanced breast cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: Borstkanker Onderzoek Groep | Conditions: Breast Neoplasm, Chemotherapy Effect | Phase 2 | Status: ACTIVE_NOT_RECRUITING